Satohiro Masuda

List of Publications by Year
in descending order

184 papers	9,882 citations	41258 49 h-index	40881 93 g-index
191 all docs	191 docs citations	191 times ranked	8678 citing authors

#	Article	IF	Citations
1	Gene Expression Levels and Immunolocalization of Organic Ion Transporters in the Human Kidney. Journal of the American Society of Nephrology: JASN, 2002, 13, 866-874.	3.0	450
2	Cellular and molecular aspects of drug transport in the kidney. Kidney International, 2000, 58, 944-958.	2.6	404
3	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Therapeutic Drug Monitoring, 2019, 41, 261-307.	1.0	374
4	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H+-organic cation antiporters. Biochemical Pharmacology, 2007, 74, 359-371.	2.0	369
5	Identification and Functional Characterization of a New Human Kidneyâ€“Specific H+/Organic Cation Antiporter, Kidney-Specific Multidrug and Toxin Extrusion 2. Journal of the American Society of Nephrology: JASN, 2006, 17, 2127-2135.	3.0	348
6	Metformin is a Superior Substrate for Renal Organic Cation Transporter OCT2 rather than Hepatic OCT1. Drug Metabolism and Pharmacokinetics, 2005, 20, 379-386.	1.1	313
7	Cisplatin and Oxaliplatin, but Not Carboplatin and Nedaplatin, Are Substrates for Human Organic Cation Transporters (SLC22A1â€“3 and Multidrug and Toxin Extrusion Family). Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 879-886.	1.3	300
8	Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3569-3574.	3.3	261
9	Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2012, 70, 399-405.	1.1	257
10	Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochemical Pharmacology, 2007, 74, 477-487.	2.0	217
11	C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics and Genomics, 2002, 12, 451-457.	5.7	186
12	Cloning and Functional Characterization of a Novel Rat Organic Anion Transporter Mediating Basolateral Uptake of Methotrexate in the Kidney. Journal of Biological Chemistry, 1996, 271, 20719-20725.	1.6	182
13	CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics and Genomics, 2004, 14, 471-478.	5.7	182
14	An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. , 2006, 112, 184-198.		173
15	Involvement of Human Multidrug and Toxin Extrusion 1 in the Drug Interaction between Cimetidine and Metformin in Renal Epithelial Cells. Journal of Pharmacology and Experimental Therapeutics, 2009, 329, 185-191.	1.3	170
16	Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transplantation, 2012, 18, 1333-1342.	1.3	168
17	Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochemical Pharmacology, 2005, 70, 1823-1831.	2.0	152
18	Down-regulation of rat organic cation transporter rOCT2 by 5/6 nephrectomy. Kidney International, 2002, 62, 514-524.	2.6	132

#	Article	IF	Citations
19	Molecular Markers of Tubulointerstitial Fibrosis and Tubular Cell Damage in Patients with Chronic Kidney Disease. PLoS ONE, 2015, 10, e0136994.	1.1	130
20	Identification and functional characterization of a novel human and rat riboflavin transporter, RFT1. American Journal of Physiology - Cell Physiology, 2008, 295, C632-C641.	2.1	126
21	Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenetics and Genomics, 2006, 16, 119-127.	0.7	125
22	SLCO4C1 Transporter Eliminates Uremic Toxins and Attenuates Hypertension and Renal Inflammation. Journal of the American Society of Nephrology: JASN, 2009, 20, 2546-2555.	3.0	124
23	Identification and Comparative Functional Characterization of a New Human Riboflavin Transporter hRFT3 Expressed in the Brain. Journal of Nutrition, 2010, 140, 1220-1226.	1.3	121
24	Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clinical Pharmacology and Therapeutics, 2001, 69, 308-316.	2.3	120
25	Molecular Cloning, Functional Characterization and Tissue Distribution of Rat H+/Organic Cation Antiporter MATE1. Pharmaceutical Research, 2006, 23, 1696-1701.	1.7	120
26	Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. Clinical Pharmacology and Therapeutics, 2000, 68, 98-103.	2.3	109
27	Therapeutic Drug Monitoring of Everolimus. Therapeutic Drug Monitoring, 2016, 38, 143-169.	1.0	102
28	INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood, 2007, 109, 306-314.	0.6	100
29	Maternal riboflavin deficiency, resulting in transient neonatal-onset glutaric aciduria Type 2, is caused by a microdeletion in the riboflavin transporter gene GPR172B. Human Mutation, 2011, 32, E1976-E1984.	1.1	96
30	Expression Levels of Renal Organic Anion Transporters (OATs) and Their Correlation with Anionic Drug Excretion in Patients with Renal Diseases. Pharmaceutical Research, 2004, 21, 61-67.	1.7	95
31	Significance of Organic Cation Transporter 3 (SLC22A3) Expression for the Cytotoxic Effect of Oxaliplatin in Colorectal Cancer. Drug Metabolism and Disposition, 2008, 36, 2299-2306.	1.7	95
32	Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clinical Pharmacology and Therapeutics, 2006, 80, 331-345.	2.3	93
33	Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenetics and Genomics, 2008, 18, 413-423.	0.7	91
34	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic Drug Monitoring, 2021, 43, 150-200.	1.0	89
35	Conformational Change in Transfer RNA Is an Early Indicator of Acute Cellular Damage. Journal of the American Society of Nephrology: JASN, 2014, 25, 2316-2326.	3.0	88
36	Transcellular transport of organic cations in double-transfected MDCK cells expressing human organic cation transporters hOCT1/hMATE1 and hOCT2/hMATE1. Biochemical Pharmacology, 2008, 76, 894-903.	2.0	86

#	Article	IF	Citations
37	mRNA distribution and membrane localization of the OAT-K1 organic anion transporter in rat renal tubules. FEBS Letters, 1997, 407, 127-131.	1.3	81
38	Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2. Biochemical Pharmacology, 2009, 78, 1263-1271.	2.0	79
39	Detection of 22 antiepileptic drugs by ultraâ€performance liquid chromatography coupled with tandem mass spectrometry applicable to routine therapeutic drug monitoring. Biomedical Chromatography, 2012, 26, 1519-1528.	0.8	77
40	Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients. Clinical Pharmacology and Therapeutics, 2005, 78, 168-181.	2.3	75
41	Differential localization of organic cation transporters rOCT1 and rOCT2 in the basolateral membrane of rat kidney proximal tubules. Histochemistry and Cell Biology, 2000, 114, 175-180.	0.8	74
42	Physiological and pharmacological implications of peptide transporters, PEPT1 and PEPT2. Nephrology Dialysis Transplantation, 2000, 15, 11-13.	0.4	71
43	Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metforminâ€induced lactic acidosis. British Journal of Pharmacology, 2012, 166, 1183-1191.	2.7	71
44	Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients. Cancer Chemotherapy and Pharmacology, 2015, 76, 989-996.	1.1	70
45	Immunosuppressive effects of tacrolimus on macrophages ameliorate experimental colitis. Inflammatory Bowel Diseases, 2010, 16, 2022-2033.	0.9	63
46	Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. International Journal of Clinical Oncology, 2016, 21, 491-497.	1.0	63
47	Involvement of autophagy in the pharmacological effects of the mTOR inhibitor everolimus in acute kidney injury. European Journal of Pharmacology, 2012, 696, 143-154.	1.7	61
48	Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules. Pharmaceutical Research, 2001, 18, 1528-1534.	1.7	60
49	Precise comparison of protein localization among OCT, OAT, and MATE in human kidney. Journal of Pharmaceutical Sciences, 2013, 102, 3302-3308.	1.6	56
50	Risk Factors for Recurrence of Primary Sclerosing Cholangitis After Living Donor Liver Transplantation: A Single Center Experience. Digestive Diseases and Sciences, 2009, 54, 1347-1354.	1.1	55
51	Vancomycin induces reactive oxygen species-dependent apoptosis via mitochondrial cardiolipin peroxidation in renal tubular epithelial cells. European Journal of Pharmacology, 2017, 800, 48-56.	1.7	52
52	Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients. Clinical Pharmacology and Therapeutics, 2006, 79, 90-102.	2.3	50
53	Organic anion transporter oatp2-mediated interaction between digoxin and amiodarone in the rat liver. Pharmaceutical Research, 2002, 19, 738-743.	1.7	49
54	Transport of guanidine compounds by human organic cation transporters, hOCT1 and hOCT2. Biochemical Pharmacology, 2009, 77, 1429-1436.	2.0	48

#	Article	IF	Citations
55	Heterozygous variants of multidrug and toxin extrusions (MATE1 and MATE2-K) have little influence on the disposition of metformin in diabetic patients. Pharmacogenetics and Genomics, 2010, 20, 135-138.	0.7	48
56	Role of mTOR Inhibitors in Kidney Disease. International Journal of Molecular Sciences, 2016, 17, 975.	1.8	47
57	Cloning and Characterization of a Novel Na+-dependent Glucose Transporter (NaGLT1) in Rat Kidney. Journal of Biological Chemistry, 2003, 278, 14669-14676.	1.6	46
58	Sodium tauroursodeoxycholate prevents paraquat-induced cell death by suppressing endoplasmic reticulum stress responses in human lung epithelial A549 cells. Biochemical and Biophysical Research Communications, 2013, 432, 689-694.	1.0	45
59	Pharmacokinetic significance of luminal multidrug and toxin extrusion 1 in chronic renal failure rats. Biochemical Pharmacology, 2007, 73, 1482-1490.	2.0	44
60	Comparison of the Anti-tumor Effects of Selective Serotonin Reuptake Inhibitors as Well as Serotonin and Norepinephrine Reuptake Inhibitors in Human Hepatocellular Carcinoma Cells. Biological and Pharmaceutical Bulletin, 2015, 38, 1410-1414.	0.6	44
61	Safety and efficacy of PD-1 inhibitors in nonâ€“small cell lung cancer patients positive for antinuclear antibodies. Lung Cancer, 2019, 130, 5-9.	0.9	44
62	Effect of CYP2C19 polymorphisms on the clinical outcome of low-dose clobazam therapy in Japanese patients with epilepsy. European Journal of Clinical Pharmacology, 2015, 71, 51-58.	0.8	43
63	Roles of the Jejunum and Ileum in the First-Pass Effect as Absorptive Barriers for Orally Administered Tacrolimus. Journal of Surgical Research, 2002, 103, 215-222.	0.8	41
64	Tacrolimus Therapy as an Alternative to Thiopurines for Maintaining Remission in Patients With Refractory Ulcerative Colitis. Journal of Clinical Gastroenterology, 2011, 45, 526-530.	1.1	41
65	Role of kidney-specific organic anion transporters in the urinary excretion of methotrexate. Kidney International, 2001, 60, 1058-1068.	2.6	40
66	Upregulation of H⁺-peptide cotransporter PEPT2 in rat remnant kidney. American Journal of Physiology - Renal Physiology, 2001, 281, F1109-F1116.	1.3	39
67	Functional analysis of rat renal organic anion transporter OAT-K1: bidirectional methotrexate transport in apical membrane. FEBS Letters, 1999, 459, 128-132.	1.3	38
68	Distinct Inhibitory Effects of Tacrolimus and Cyclosporin A on Calcineurin Phosphatase Activity. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 816-825.	1.3	38
69	Impact of IntestinalCYP2C19Genotypes on the Interaction between Tacrolimus and Omeprazole, but Not Lansoprazole, in Adult Living-Donor Liver Transplant Patients. Drug Metabolism and Disposition, 2009, 37, 821-826.	1.7	38
70	Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events. Scientific Reports, 2021, 11, 1324.	1.6	38
71	Distribution characteristics of levofloxacin and grepafloxacin in rat kidney. Pharmaceutical Research, 1999, 16, 534-539.	1.7	37
72	Decreased expression of P-glycoprotein during differentiation in the human intestinal cell line Caco-2. Biochemical Pharmacology, 2003, 66, 163-170.	2.0	37

#	Article	IF	Citations
73	Urinary Neutrophil Gelatinase-Associated Lipocalin: A Useful Biomarker for Tacrolimus-Induced Acute Kidney Injury in Liver Transplant Patients. PLoS ONE, 2014, 9, e110527.	1.1	36
74	Clinical prospects of biomarkers for the early detection and/or prediction of organ injury associated with pharmacotherapy. Biochemical Pharmacology, 2019, 170, 113664.	2.0	36
75	Pharmacokinetic Significance of Renal OAT3 (SLC22A8) for Anionic Drug Elimination in Patients with Mesangial Proliferative Glomerulonephritis. Pharmaceutical Research, 2005, 22, 2016-2022.	1.7	35
76	Delayed Effect of Grapefruit Juice on Pharmacokinetics and Pharmacodynamics of Tacrolimus in a Living-Donor Liver Transplant Recipient. Drug Metabolism and Pharmacokinetics, 2006, 21, 122-125.	1.1	35
77	Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients*1. Clinical Pharmacology and Therapeutics, 2004, 75, 352-361.	2.3	33
78	Transcellular Transport of Creatinine in Renal Tubular Epithelial Cell Line LLC-PK1. Drug Metabolism and Pharmacokinetics, 2005, 20, 200-205.	1.1	32
79	Excessive spinal glutamate transmission is involved in oxaliplatin-induced mechanical allodynia: a possibility for riluzole as a prophylactic drug. Scientific Reports, 2017, 7, 9661.	1.6	32
80	Decreased Expression of Glucose and Peptide Transporters in Rat Remnant Kidney. Drug Metabolism and Pharmacokinetics, 2004, 19, 41-47.	1.1	31
81	Influence of Cytochrome P450 (CYP) <i>3A4*1G</i> Polymorphism on the Pharmacokinetics of Tacrolimus, Probability of Acute Cellular Rejection, and mRNA Expression Level of CYP3A5 Rather than CYP3A4 in Living-Donor Liver Transplant Patients. Biological and Pharmaceutical Bulletin, 2013, 36, 1814-1821.	0.6	31
82	Urinary chemokine (C-C motif) ligand 2 (monocyte chemotactic protein-1) as a tubular injury marker for early detection of cisplatin-induced nephrotoxicity. Biochemical Pharmacology, 2013, 85, 570-582.	2.0	30
83	Interaction between Tacrolimus and Lansoprazole, but not Rabeprazole in Living-Donor Liver Transplant Patients with Defects of CYP2C19 and CYP3A5. Drug Metabolism and Pharmacokinetics, 2008, 23, 134-138.	1.1	29
84	Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation. Pharmacogenetics and Genomics, 2014, 24, 356-366.	0.7	29
85	Pirfenidone alleviates lung ischemia-reperfusion injury in a rat model. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, 289-296.	0.4	29
86	Common single nucleotide polymorphisms of the MDR1 gene have no influence on its mRNA expression level of normal kidney cortex and renal cell carcinoma in Japanese nephrectomized patients. Journal of Human Genetics, 2004, 49, 40-45.	1.1	28
87	Enhanced expression of enterocyte P-glycoprotein depresses cyclosporine bioavailability in a recipient of living donor liver transplantation. Liver Transplantation, 2003, 9, 1108-1113.	1.3	27
88	Transient up-regulation of P-glycoprotein reduces tacrolimus absorption after ischemiaâ€“reperfusion injury in rat ileum. Biochemical Pharmacology, 2005, 69, 561-568.	2.0	27
89	Sensitive and validated LCâ€MS/MS methods to evaluate mycophenolic acid pharmacokinetics and pharmacodynamics in hematopoietic stem cell transplant patients. Biomedical Chromatography, 2015, 29, 1309-1316.	0.8	27
90	Na+-dependent fructose transport via rNaGLT1 in rat kidney. FEBS Letters, 2003, 546, 276-280.	1.3	25

#	Article	IF	Citations
91	mTOR inhibitor everolimus ameliorates progressive tubular dysfunction in chronic renal failure rats. Biochemical Pharmacology, 2010, 79, 67-76.	2.0	25
92	Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 886-891.	1.4	25
93	Recent Topics on The Mechanisms of Immunosuppressive Therapy-Related Neurotoxicities. International Journal of Molecular Sciences, 2019, 20, 3210.	1.8	25
94	Initial Dosage Adjustment for Oral Administration of Tacrolimus Using the Intestinal MDR1 Level in Living-Donor Liver Transplant Recipients. Transplantation Proceedings, 2005, 37, 1728-1729.	0.3	24
95	Time Course of Calcium Concentrations and Risk Factors for Hypocalcemia in Patients Receiving Denosumab for the Treatment of Bone Metastases From Cancer. Annals of Pharmacotherapy, 2014, 48, 1159-1165.	0.9	23
96	Inhibitory effect of ciprofloxacin on Î²â€glucuronidaseâ€mediated deconjugation of mycophenolic acid glucuronide. Biopharmaceutics and Drug Disposition, 2014, 35, 275-283.	1.1	23
97	Impact of CYP3A5, POR, and CYP2C19 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplantation. International Journal of Molecular Sciences, 2019, 20, 2413.	1.8	23
98	Cyclosporine exposure and calcineurin phosphatase activity in living-donor liver transplant patients: Twice daily vs. once daily dosing. Liver Transplantation, 2006, 12, 292-300.	1.3	22
99	Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers. International Journal of Clinical Oncology, 2007, 12, 284-290.	1.0	22
100	Biomarkers for individualized dosage adjustments in immunosuppressive therapy using calcineurin inhibitors after organ transplantation. Acta Pharmacologica Sinica, 2019, 40, 151-159.	2.8	22
101	Functional Characteristics and Pharmacokinetic Significance of Kidney-specific Organic Anion Transporters, OAT-K1 and OAT-K2, in the Urinary Excretion of Anionic Drugs. Drug Metabolism and Pharmacokinetics, 2003, 18, 91-103.	1.1	21
102	A Retrospective Analysis of Vancomycin Pharmacokinetics in Japanese Cancer and Non-cancer Patients Based on Routine Trough Monitoring Data. Biological and Pharmaceutical Bulletin, 2009, 32, 99-104.	0.6	21
103	Assessment of Four Methodologies (Microparticle Enzyme Immunoassay, Chemiluminescent Enzyme) Tj ETQq1 1 0.784314 rgBT /Ove Transplantation Proceedings, 2014, 46, 758-760.	0.3	20
104	Disruption of Slc52a3 gene causes neonatal lethality with riboflavin deficiency in mice. Scientific Reports, 2016, 6, 27557.	1.6	20
105	Developmental trajectory of intestinal <scp>MDR1/ABCB1</scp> mRNA expression in children. British Journal of Clinical Pharmacology, 2014, 77, 910-912.	1.1	19
106	Association between CYP3A5 Genotypes in Graft Liver and Increase in Tacrolimus Biotransformation from Steroid Treatment in Living-donor Liver Transplant Patients. Drug Metabolism and Pharmacokinetics, 2014, 29, 83-89.	1.1	19
107	MDR1 Haplotypes Conferring an Increased Expression of Intestinal CYP3A4 Rather than MDR1 in Female Living-Donor Liver Transplant Patients. Pharmaceutical Research, 2009, 26, 1590-1595.	1.7	18
108	Risk Factors for Predicting Severe Neutropenia Induced by Pemetrexed Plus Carboplatin Therapy in Patients with Advanced Non-small Cell Lung Cancer. Biological and Pharmaceutical Bulletin, 2015, 38, 1192-1198.	0.6	18

#	Article	IF	Citations
109	Decreased Renal Accumulation and Toxicity of a New VCM Formulation in Rats with Chronic Renal Failure. Drug Metabolism and Pharmacokinetics, 2007, 22, 419-427.	1.1	17
110	Significance of trough monitoring for tacrolimus blood concentration and calcineurin activity in adult patients undergoing primary living-donor liver transplantation. European Journal of Clinical Pharmacology, 2012, 68, 259-266.	0.8	17
111	Statin Intolerance Clinical Guide 2018. Journal of Atherosclerosis and Thrombosis, 2020, 27, 375-396.	0.9	17
112	Relation between mRNA Expression Level of Multidrug Resistance 1/ABCB1 in Blood Cells and Required Level of Tacrolimus in Pediatric Living-Donor Liver Transplantation. Journal of Pharmacology and Experimental Therapeutics, 2008, 325, 610-616.	1.3	16
113	Expression of Peptide Transporter Following Intestinal Transplantation in the Rat. Journal of Surgical Research, 2001, 99, 294-300.	0.8	15
114	Gene expression variance based on random sequencing in rat remnant kidney. Kidney International, 2004, 66, 29-45.	2.6	15
115	Required Transient Dose Escalation of Tacrolimus in Living-Donor Liver Transplant Recipients with High Concentrations of a Minor Metabolite M-II in Bile. Drug Metabolism and Pharmacokinetics, 2008, 23, 313-317.	1.1	15
116	Renal Tubular Secretion of Varenicline by Multidrug and Toxin Extrusion (MATE) Transporters. Drug Metabolism and Pharmacokinetics, 2012, 27, 563-569.	1.1	15
117	Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 2020, 86, 803-813.	1.1	14
118	Inter-laboratory Variability of Current Immunoassay Methods for Tacrolimus among Japanese Hospitals. Biological and Pharmaceutical Bulletin, 2016, 39, 1331-1337.	0.6	13
119	Impact of Cyclin B2 and Cell division cycle 2 on tubular hyperplasia in progressive chronic renal failure rats. American Journal of Physiology - Renal Physiology, 2010, 298, F923-F934.	1.3	12
120	Involvement of riboflavin transporter RFVT2/Slc52a2 in hepatic homeostasis of riboflavin in mice. European Journal of Pharmacology, 2013, 714, 281-287.	1.7	12
121	Population Pharmacokinetics of Everolimus in Relation to Clinical Outcomes in Patients With Advanced Renal Cell Carcinoma. Therapeutic Drug Monitoring, 2016, 38, 663-669.	1.0	12
122	Evaluation of Teicoplanin Trough Values After the Recommended Loading Dose in Children With Associated Safety Analysis. Pediatric Infectious Disease Journal, 2017, 36, 398-400.	1.1	12
123	Effect of Intestinal and Hepatic First-pass Extraction on the Pharmacokinetics of Everolimus in Rats. Drug Metabolism and Pharmacokinetics, 2008, 23, 469-475.	1.1	11
124	Evaluation of teicoplanin concentrations and safety analysis in neonates. International Journal of Antimicrobial Agents, 2014, 44, 458-462.	1.1	11
125	Protective Effects of Imatinib on Ischemia/Reperfusion Injury in Rat Lung. Annals of Thoracic Surgery, 2016, 102, 1717-1724.	0.7	11
126	Analysis of the variable factors influencing tacrolimus blood concentration during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation. International Journal of Hematology, 2017, 105, 361-368.	0.7	11

#	Article	IF	Citations
127	Absence of Influence of Concomitant Administration of Rabeprazole on the Pharmacokinetics of Tacrolimus in Adult Living-donor Liver Transplant Patients: A Caseâ€“control Study. Drug Metabolism and Pharmacokinetics, 2009, 24, 458-463.	1.1	10
128	Significant effect of age on docetaxel pharmacokinetics in Japanese female breast cancer patients by using the population modeling approach. European Journal of Clinical Pharmacology, 2016, 72, 703-710.	0.8	10
129	Influence of Pharmaceutical Formulation on the Mucosal Concentration of 5-Aminosalicylic Acid and <i>N</i>-Acetylmesalamine in Japanese Patients with Ulcerative Colitis. Biological and Pharmaceutical Bulletin, 2019, 42, 81-86.	0.6	10
130	Influence of POR*28 Polymorphisms on CYP3A5*3-Associated Variations in Tacrolimus Blood Levels at an Early Stage after Liver Transplantation. International Journal of Molecular Sciences, 2020, 21, 2287.	1.8	10
131	Comparison of 4 Commercial Immunoassays Used in Measuring the Concentration of Tacrolimus in Blood and Their Cross-Reactivity to Its Metabolites. Therapeutic Drug Monitoring, 2020, 42, 400-406.	1.0	9
132	Increased protein level of PEPT1 intestinal H+-peptide cotransporter upregulates absorption of glycylsarcosine and ceftibuten in 5/6 nephrectomized rats. American Journal of Physiology - Renal Physiology, 2005, 288, G664-G670.	1.6	8
133	Impact of glutathione S-transferase T1 gene polymorphisms on acute cellular rejection in living donor liver transplantation. Transplant Immunology, 2013, 28, 14-17.	0.6	8
134	Association of decreased mRNA expression of multidrug and toxin extrusion protein 1 in peripheral blood cells with the development of flutamide-induced liver injury. Cancer Chemotherapy and Pharmacology, 2015, 75, 1191-1197.	1.1	8
135	Urinary Dopamine as a Potential Index of the Transport Activity of Multidrug and Toxin Extrusion in the Kidney. International Journal of Molecular Sciences, 2016, 17, 1228.	1.8	8
136	Pharmacokinetics and Pharmacodynamics of Once-Daily Tacrolimus Compared With Twice-Daily Tacrolimus in the Early Stage After Living Donor Liver Transplantation. Therapeutic Drug Monitoring, 2018, 40, 675-681.	1.0	8
137	Effectiveness of Sirolimus in Combination with Cyclosporine against Chronic Rejection in a Pediatric Liver Transplant Patient. Biological and Pharmaceutical Bulletin, 2013, 36, 1221-1225.	0.6	7
138	Evaluation of the Potency of Telaprevir and Its Metabolites as Inhibitors of Renal Organic Cation Transporters, a Potential Mechanism for the Elevation of Serum Creatinine. Drug Metabolism and Pharmacokinetics, 2014, 29, 266-271.	1.1	7
139	Successful Telaprevir Treatment in Combination of Cyclosporine against Recurrence of Hepatitis C in the Japanese Liver Transplant Patients. Biological and Pharmaceutical Bulletin, 2014, 37, 417-423.	0.6	7
140	Differences in recognition of similar medication names between pharmacists and nurses: a retrospective study. Journal of Pharmaceutical Health Care and Sciences, 2015, 1, 19.	0.4	7
141	Involvement of intracellular cAMP in epirubicin-induced vascular endothelial cell injury. Journal of Pharmacological Sciences, 2016, 130, 33-37.	1.1	7
142	Calcineurin inhibitors exacerbate coronary arteritis via the MyD88 signalling pathway in a murine model of Kawasaki disease. Clinical and Experimental Immunology, 2017, 190, 54-67.	1.1	7
143	Riluzole prevents oxaliplatin-induced cold allodynia via inhibition of overexpression of transient receptor potential melastatin 8 in rats. Journal of Pharmacological Sciences, 2018, 138, 214-217.	1.1	7
144	Urinary Human Epididymis Secretory Protein 4 as a Useful Biomarker for Subclinical Acute Rejection Three Months after Kidney Transplantation. International Journal of Molecular Sciences, 2019, 20, 4699.	1.8	6

#	Article	IF	Citations
145	Significance of Ethnic Factors in Immunosuppressive Therapy Management After Organ Transplantation. Therapeutic Drug Monitoring, 2020, 42, 369-380.	1.0	6
146	Donor CYP3A5 Gene Polymorphism Alone Cannot Predict Tacrolimus Intrarenal Concentration in Renal Transplant Recipients. International Journal of Molecular Sciences, 2020, 21, 2976.	1.8	6
147	Temporal Decline in Sirolimus Elimination Immediately After Pancreatic Islet Transplantation. Drug Metabolism and Pharmacokinetics, 2006, 21, 492-500.	1.1	5
148	Relationship between incident types and impact on patients in drug name errors: a correlational study. Journal of Pharmaceutical Health Care and Sciences, 2015, 1, 11.	0.4	5
149	Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402). Oncology, 2018, 94, 289-296.	0.9	5
150	CYP3A5 Genotype as a Potential Pharmacodynamic Biomarker for Tacrolimus Therapy in Ulcerative Colitis in Japanese Patients. International Journal of Molecular Sciences, 2020, 21, 4347.	1.8	5
151	Evaluation of Calvert's Formula for Dosage Adjustment of Carboplatin in Japanese Patients with Hormone Refractory Prostate Cancer. Biological and Pharmaceutical Bulletin, 2006, 29, 1441-1444.	0.6	4
152	Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats. Biopharmaceutics and Drug Disposition, 2009, 30, 517-523.	1.1	4
153	The challenge of acute rejection in intestinal transplantation. Pediatric Surgery International, 2012, 28, 855-859.	0.6	4
154	Cytokine gene polymorphisms in acute cellular rejection following living donor liver transplantation: analysis of 155 donor-recipient pairs. Hepatology International, 2013, 7, 916-922.	1.9	4
155	Establishment of an experimental rat model of tacrolimus-induced kidney injury accompanied by interstitial fibrosis. Toxicology Letters, 2021, 341, 43-50.	0.4	4
156	Effects of Concomitant Administration of Vonoprazan Fumarate on the Tacrolimus Blood Concentration in Kidney Transplant Recipients. Biological and Pharmaceutical Bulletin, 2020, 43, 1600-1603.	0.6	4
157	Analysis of Questions on Out-of-hospital Prescriptions Related to Laboratory Data. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2018, 44, 229-235.	0.0	4
158	Development and Utility Evaluation of a Compatibility Chart of Injections Commonly Used in the Intensive Care Unit. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2016, 42, 286-294.	0.0	4
159	Larger Dosage Required for Everolimus than Sirolimus to Maintain Same Blood Concentration in Two Pancreatic Islet Transplant Patients with Tacrolimus. Drug Metabolism and Pharmacokinetics, 2009, 24, 175-179.	1.1	3
160	Inhibitory effects of vandetanib on creatinine transport via renal organic cation transporter OCT2. European Journal of Pharmaceutical Sciences, 2021, 158, 105666.	1.9	3
161	A randomized, double-blind, placebo-controlled phase II study of prophylactic dexamethasone (dex) therapy for fatigue and malaise due to regorafenib in patient (pts) with metastatic colorectal cancer (mCRC): (KSCC1402/HGCSG1402).. Journal of Clinical Oncology, 2016, 34, 10127-10127.	0.8	3
162	Effect of Itraconazole and Its Metabolite Hydroxyitraconazole on the Blood Concentrations of Cyclosporine and Tacrolimus in Lung Transplant Recipients. Biological and Pharmaceutical Bulletin, 2022, 45, 397-402.	0.6	3

#	Article	IF	Citations
163	Time-saving multiplex detection of single nucleotide polymorphisms by ultrasensitive DNA microarray. Journal of Biochemistry, 2010, 148, 557-563.	0.9	2
164	Association of interleukin4 gene polymorphisms of recipients and donors with acute rejection following living donor liver transplantation. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 179-185.	0.7	2
165	Neutrophil Gelatinase-Associated Lipocalin Is Not Associated with Tacrolimus-Induced Acute Kidney Injury in Liver Transplant Patients Who Received Mycophenolate Mofetil with Delayed Introduction of Tacrolimus. International Journal of Molecular Sciences, 2019, 20, 3103.	1.8	2
166	Effects of Diluent Volume and Administration Time on the Incidence of Anaphylaxis Following Docetaxel Therapy in Breast Cancer. Biological and Pharmaceutical Bulletin, 2020, 43, 663-668.	0.6	2
167	Pharmacokinetic Interactions between Calcineurin Inhibitors and Azole Antifungals in Hematopoietic Stem Cell Transplant Recipients. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and) Tj ETQq1 1 0.784314 rgBT /Overlock	0.4	1
168	Interaction of Azole Antifungal Agents with Human P-glycoprotein Expressed in a Kidney Epithelial Cell Line, LLC-PK1.. Drug Metabolism and Pharmacokinetics, 2001, 16, 5-11.	0.0	1
169	Drug delivery system in treatment against inflammatory bowel disease: present and future. Drug Delivery System, 2018, 33, 397-405.	0.0	1
170	Increasing Diluent Volume Decreases Bendamustine-Induced Venous Irritation without Reducing the Therapeutic Efficacy. Biological and Pharmaceutical Bulletin, 2020, 43, 488-492.	0.6	1
171	Vancomycin induced renal tubular cell injury by reactive oxygen species generation and mitochondrial dysfunction. FASEB Journal, 2015, 29, 777.1.	0.2	1
172	Elucidation of Occurrence Mechanism of Dispensing Errors Based on Gaze Movement of Pharmacists Using Eye Tracking Method. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and) Tj ETQq0 0 0 rgBT /Overlock	0.4	1
173	Prophylactic effect of calcium channel blockers against oxaliplatinâ€induced acute peripheral neuropathy (1143.8). FASEB Journal, 2014, 28, 1143.8.	0.2	0
174	Association between decreased expression of GLTâ€1 derived spinal glutamate accumulation and oxaliplatinâ€induced mechanical allodynia (1143.1). FASEB Journal, 2014, 28, 1143.1.	0.2	0
175	Evaluation of Patient Education System to Improve Their Understanding in Patients Treated with Erlotinib or Gefitinib. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2015, 41, 566-577.	0.0	0
176	Excessive spinal glutamate transmission is involved in oxaliplatin-induced mechanical allodynia in rats. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-2-31.	0.0	0
177	Novel high-sensitive drug detecting, PID method reveals intra-tumor pharmacokinetics of trastuzumab and factors affect to its remarkable heterogeneity. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-11-18.	0.0	0
178	Role of mTOR inhibitors in solid organ transplantation. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY52-2.	0.0	0
179	Relationship between autophagy and acute rejection after kidney transplant. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-3-14.	0.0	0
180	Patient reported outcomes (PRO) results for prophylactic effect of dexamethasone on regorafenib-related fatigue and/or malaise: a randomized, placebo-controlled, double-blind clinical study in patients with unresectable metastatic colorectal cancer: KSCC1402/HGCSG1402.. Journal of Clinical Oncology, 2018, 36, 10094-10094.	0.8	0

#	Article	IF	Citations
181	Specification of Start Timing of Medication Support in Patients with Rheumatoid Arthritis. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2018, 44, 261-269.	0.0	0
182	Analysis of Adverse Drug Reactions on Osimertinib in T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2018, 44, 355-362.	0.0	0
183	The 2nd Symposium â€œCurrent Status of Reverse Translational Research Conducted by Hospital Pharmacistsâ€•ï½žChallenges for Screening of Therapeutic Molecular Target and Personalized Medicineï½ž. Yakugaku Zasshi, 2019, 139, 899-900.	0.0	0
184	IMMU-09. NIVOLUMAB THERAPY FOR A PEDIATRIC-ONSET PRIMARY INTRACRANIAL MELANOMA. Neuro-Oncology, 2020, 22, iii361-iii361.	0.6	0